TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Analyst Ratings

NYSE:TEVA • US8816242098

33.92 USD
-0.39 (-1.14%)
At close: Feb 12, 2026
33.7038 USD
-0.22 (-0.64%)
After Hours: 2/12/2026, 5:21:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Buy % Consensus

83

ChartMill assigns a Buy % Consensus number of 83% to TEVA. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 0.11. This target is -99.67% below the current price.
  • TEVA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TEVA.
  • In the previous month the buy percentage consensus was at a similar level.
  • TEVA was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

Find peers with buy consensus above 85%
TEVA Historical Analyst RatingsTEVA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Price Target & Forecast

Price Low Median Mean High 33.920.110.110.110.12 - -99.67% -99.67% -99.67% -99.66%

Related screens

Find peers 30% below price target
TEVA Current Analyst RatingTEVA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2026-02-09 Goldman Sachs Maintains Buy -> Buy
2026-01-30 Barclays Maintains Overweight -> Overweight
2026-01-29 ScotiaBank Maintains Sector Outperform -> Sector Outperform
2026-01-29 Truist Securities Maintains Buy -> Buy
2026-01-06 Jefferies Maintains Buy -> Buy
2025-12-22 Piper Sandler Maintains Overweight -> Overweight
2025-12-19 Goldman Sachs Maintains Buy -> Buy
2025-12-16 JP Morgan Maintains Overweight -> Overweight
2025-12-09 Barclays Initiate Overweight
2025-12-09 B of A Securities Maintains Buy -> Buy
2025-12-08 Goldman Sachs Maintains Buy -> Buy
2025-12-05 ScotiaBank Initiate Sector Outperform
2025-11-06 JP Morgan Maintains Overweight -> Overweight
2025-10-03 JP Morgan Maintains Overweight -> Overweight
2025-09-24 UBS Maintains Buy -> Buy
2025-06-26 UBS Maintains Buy -> Buy
2025-06-06 Goldman Sachs Initiate Buy
2025-05-28 Truist Securities Initiate Buy
2025-05-12 JP Morgan Upgrade Neutral -> Overweight
2025-05-08 B of A Securities Maintains Buy -> Buy
2025-03-06 B of A Securities Maintains Buy -> Buy
2025-01-30 UBS Maintains Buy -> Buy
2025-01-30 Barclays Maintains Overweight -> Overweight
2025-01-23 UBS Maintains Buy -> Buy
2025-01-17 Piper Sandler Maintains Overweight -> Overweight
2024-12-18 Barclays Maintains Overweight -> Overweight
2024-10-23 Barclays Maintains Overweight -> Overweight
2024-10-21 JP Morgan Maintains Neutral -> Neutral
2024-09-03 UBS Maintains Buy -> Buy
2024-08-01 Barclays Maintains Overweight -> Overweight

TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ

What is the price target for TEVA stock?

7 analysts have analysed TEVA and the average price target is 0.11 USD. This implies a price decrease of -99.67% is expected in the next year compared to the current price of 33.92.


What is the consensus rating for TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

The consensus rating for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.


What is the number of analysts for TEVA stock?

The number of analysts covering TEVA PHARMACEUTICAL-SP ADR (TEVA) is 7.